Top

Supportive Care in Cancer

Published in:

01-09-2016 | Original Article

Risk of secondary lymphedema in breast cancer survivors is related to serum phospholipid fatty acid desaturation

Authors: Eunjung Ryu, Seung Yun Yim, Hyun Ju Do, Jae-Young Lim, Eun Joo Yang, Min-Jeong Shin, Seung-Min Lee

Published in: Supportive Care in Cancer | Issue 9/2016

Abstract

Purpose

Secondary lymphedema is a common irreversible side effect of breast cancer surgery. We investigated if risk of secondary lymphedema in breast cancer survivors was related to changes in serum phospholipid fatty acid composition.

Methods

Study subjects were voluntarily recruited into the following three groups: breast cancer survivors who had sentinel lymph node biopsy without lymphedema (SLNB), those who had auxillary lymph node dissection without lymphedema (ALND), and those who had ALND with lymphedema (ALND + LE). Body mass index (BMI), serum lipid profiles, bioimpedance data with single-frequency bioimpedance analysis (SFBIA), and serum phospholipid compositions were analyzed and compared among the groups.

Results

BMI, serum total cholesterol (total-C), and low-density lipoprotein cholesterol (LDL-C) and SFBIA ratios increased only in the ALND + LE. High polyunsaturated fatty acids (PUFAs) and high C20:4 to C18:2 n-6 PUFAs (arachidonic acid [AA]/linoleic acid [LA]) was detected in the ALND and ALND + LE groups compared to SLNB. The ALND + LE group showed increased activity indices for delta 6 desaturase (D6D) and D5D and increased ratio of AA to eicosapentaenoic acid (AA/EPA) compared to the ALND and SLNB groups. Correlation and regression analysis indicated that D6D, D5D, and AA/EPA were associated with SFBIA ratios.

Conclusion

We demonstrated that breast cancer survivors with lymphedema had elevated total PUFAs, fatty acid desaturase activity indices, and AA/EPA in serum phospholipids. Our findings suggested that desaturation extent of fatty acid composition might be related to the risk of secondary lymphedema in breast cancer survivors.

Soria P, Cuesta A, Romero H, Martinez FJ, Sastre A (1994) Dietary treatment of lymphedema by restriction of long-chain triglycerides. Angiology 45:703–707CrossRefPubMed

Brennan MJ, DePompolo RW, FH G (1996) Focused review: postmastectomy lymphedema. Arch Phys Med Rehabil 77:S74–S80CrossRefPubMed

Golshan M, Martin WJ, Dowlatshahi K (2003) Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. Am Surg 69:209–211 discussion 212PubMed

McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol Off J Am Soc Clin Oncol 26:5213–5219CrossRef

Carmichael AR (2006) Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG 113:1160–1166CrossRefPubMed

Werner RS, McCormick B, Petrek J, Cox L, Cirrincione C, Gray JR, Yahalom J (1991) Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 180:177–184CrossRefPubMed

Rockson SG (2013) The lymphatics and the inflammatory response: lessons learned from human lymphedema. Lymphat Res Biol 11:117–120CrossRefPubMedPubMedCentral

Brorson H (2003) Liposuction in arm lymphedema treatment. Scand J Surg 92:287–295PubMed

Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G (2005) Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet 37:1072–1081CrossRefPubMed

10.

Calder PC (2011) Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 668(Suppl 1):S50–S58CrossRefPubMed

11.

Ma DW (2007) Lipid mediators in membrane rafts are important determinants of human health and disease. Appl Physiol Nutr Metab 32:341–350CrossRefPubMed

12.

Schmitz G, Ecker J (2008) The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 47:147–155CrossRefPubMed

13.

Storlien LH, Hulbert AJ, Else PL (1998) Polyunsaturated fatty acids, membrane function and metabolic diseases such as diabetes and obesity. Curr Opin Clin Nutr Metab Care 1:559–563CrossRefPubMed

14.

Cinti DL, Cook L, Nagi MN, SK S (1992) The fatty acid chain elongation system of mammalian endoplasmic reticulum. Prog Lipid Res 31:1–51CrossRefPubMed

15.

Obukowicz MG, Welsch DJ, Salsgiver WJ, Martin-Berger CL, Chinn KS, Duffin KL, Raz A, Needleman P (1998) Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. J Pharmacol Exp Ther 287:157–166PubMed

16.

Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, Shirai S, Kondo K, Sakai K, Goya M, Iwabuchi M, Ueeda M, Nobuyoshi M (2012) Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J 76:423–429CrossRefPubMed

17.

International Society of L (2013) The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 46:1–11

18.

Folch J, Lees M, GH SS (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509PubMed

19.

Bligh EG, WJ D (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917CrossRefPubMed

20.

Lepage G, CC R (1986) Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 27:114–120PubMed

21.

Inoue N, Nagao K, Hirata J, Wang YM, Yanagita T (2004) Conjugated linoleic acid prevents the development of essential hypertension in spontaneously hypertensive rats. Biochem Biophys Res Commun 323:679–684CrossRefPubMed

22.

Vessby B, Gustafsson IB, Tengblad S, Boberg M, Andersson A (2002) Desaturation and elongation of fatty acids and insulin action. Ann N York Acad Sci 967:183–195CrossRef

23.

Peter A, Cegan A, Wagner S, Lehmann R, Stefan N, Konigsrainer A, Konigsrainer I, Haring HU, Schleicher E (2009) Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. Clin Chem 55:2113–2120CrossRefPubMed

24.

Martinelli N, Girelli D, Malerba G, Guarini P, Illig T, Trabetti E, Sandri M, Friso S, Pizzolo F, Schaeffer L, Heinrich J, Pignatti PF, Corrocher R, Olivieri O (2008) FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr 88:941–949PubMed

25.

Brand A, Bauer NG, Hallott A, Goldbaum O, Ghebremeskel K, Reifen R, Richter-Landsberg C (2010) Membrane lipid modification by polyunsaturated fatty acids sensitizes oligodendroglial OLN-93 cells against oxidative stress and promotes up-regulation of heme oxygenase-1 (HSP32). J Neurochem 113:465–476CrossRefPubMed

26.

Brand A, Gil S, Seger R, Yavin E (2001) Lipid constituents in oligodendroglial cells alter susceptibility to H2O2-induced apoptotic cell death via ERK activation. J Neurochem 76:910–918CrossRefPubMed

27.

Cao D, Xue R, J X, Liu Z (2005) Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures. J Nutr Biochem 16:538–546CrossRefPubMed

28.

Siems WG, Brenke R, Beier A, Grune T (2002) Oxidative stress in chronic lymphoedema. QJM 95:803–809CrossRefPubMed

29.

Chan PH, RA F (1978) Brain edema: induction in cortical slices by polyunsaturated fatty acids. Science 201:358–360CrossRefPubMed

30.

Brasitus TA, Davidson NO, Schachter D (1985) Variations in dietary triacylglycerol saturation alter the lipid composition and fluidity of rat intestinal plasma membranes. Biochim Biophys Acta 812:460–472CrossRefPubMed

31.

Saadatian-Elahi M, Toniolo P, Ferrari P, Goudable J, Akhmedkhanov A, Zeleniuch-Jacquotte A, Riboli E (2002) Serum fatty acids and risk of breast cancer in a nested case-control study of the New York University Women’s Health Study. Cancer Epidemiol Biomark Prev 11:1353–1360

32.

Thiebaut AC, Rotival M, Gauthier E, Lenoir GM, Boutron-Ruault MC, Joulin V, Clavel-Chapelon F, Chajes V (2009) Correlation between serum phospholipid fatty acids and dietary intakes assessed a few years earlier. Nutr Cancer 61:500–509CrossRefPubMed

33.

Pala V, Krogh V, Muti P, Chajes V, Riboli E, Micheli A, Saadatian M, Sieri S, Berrino F (2001) Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J Natl Cancer Inst 93:1088–1095CrossRefPubMed

34.

Zurier RB (1993) Fatty acids, inflammation and immune responses. Prostaglandins Leukot Essent Fat Acids 48:57–62CrossRef

35.

Cleland LG, French JK, Betts WH, Murphy GA, MJ E (1988) Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol 15:1471–1475PubMed

36.

Lee TH, Hoover RL, Williams JD, Sperling RI, Ravalese J 3rd, Spur BW, Robinson DR, Corey EJ, Lewis RA, KF A (1985) Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. New Engl J Med 312:1217–1224CrossRefPubMed

37.

Prickett JD, Robinson DR, Steinberg AD (1981) Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB × NZW F1 mice. J Clin Invest 68:556–559CrossRefPubMedPubMedCentral

38.

Raederstorff D, Pantze M, Bachmann H, Moser U (1996) Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation. Int Arch Allergy Immunol 111:284–290CrossRefPubMed

39.

Torres-Guzman AM, Morado-Urbina CE, Alvarado-Vazquez PA, Acosta-Gonzalez RI, Chavez-Pina AE, Montiel-Ruiz RM, Jimenez-Andrade JM (2014) Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of complete Freund’s adjuvant-induced knee arthritis. Arthritis Res Ther 16:R64CrossRefPubMedPubMedCentral

40.

Lambert IH, Hoffmann EK, Christensen P (1987) Role of prostaglandins and leukotrienes in volume regulation by Ehrlich ascites tumor cells. J Membr Biol 98:247–256CrossRefPubMed

41.

Thoroed SM, Lauritzen L, Lambert IH, Hansen HS, Hoffmann EK (1997) Cell swelling activates phospholipase A2 in Ehrlich ascites tumor cells. J Membr Biol 160:47–58CrossRefPubMed

42.

Eveloff JL, DG W (1987) Activation of ion transport systems during cell volume regulation. Am J Phys 252:F1–10

43.

Warensjo E, Rosell M, Hellenius ML, Vessby B, De Faire U, Riserus U (2009) Associations between estimated fatty acid desaturase activities in serum lipids and adipose tissue in humans: links to obesity and insulin resistance. Lipids Health Dis 8:37CrossRefPubMedPubMedCentral

44.

Obukowicz M, Welsch D, Salsgiver W, Martin-Berger C, Chinn K, Duffin K, Raz A, Needleman P (1999) Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. Lipids 34(Suppl):S149CrossRefPubMed

45.

Obukowicz MG, Raz A, Pyla PD, Rico JG, Wendling JM, Needleman P (1998) Identification and characterization of a novel delta6/delta5 fatty acid desaturase inhibitor as a potential anti-inflammatory agent. Biochem Pharmacol 55:1045–1058CrossRefPubMed

46.

Chapkin RS, KJ C (1991) Utilization of gammalinolenic acid by mouse peritoneal macrophages. Biochim Biophys Acta 1085:365–370CrossRefPubMed

47.

Kirtland SJ (1988) Prostaglandin E1: a review. Prostaglandins Leukot Essent Fat Acids 32:165–174CrossRef

48.

Ward LC, Bunce IH, Cornish BH, Mirolo BR, Thomas BJ, LC J (1992) Multi-frequency bioelectrical impedance augments the diagnosis and management of lymphoedema in post-mastectomy patients. Eur J Clin Investig 22:751–754CrossRef

49.

Warren AG, Janz BA, Slavin SA, LJ B (2007) The use of bioimpedance analysis to evaluate lymphedema. Ann Plast Surg 58:541–543CrossRefPubMed

Title: Risk of secondary lymphedema in breast cancer survivors is related to serum phospholipid fatty acid desaturation
Authors: Eunjung Ryu
Seung Yun Yim
Hyun Ju Do
Jae-Young Lim
Eun Joo Yang
Min-Jeong Shin
Seung-Min Lee
Publication date: 01-09-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 9/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3197-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2016

Agreement between personally generated areas of quality of life concern and standard outcome measures in people with advanced cancer

Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents

Scalp cooling: a qualitative study to assess the perceptions and experiences of Australian patients with breast cancer

Cancer patient age and family caregiver bereavement outcomes

Who experiences higher and increasing breathlessness in advanced cancer? The longitudinal EPCCS Study

Physical activity and health-related quality of life in pediatric cancer patients following a 4-week inpatient rehabilitation program

Keynote webinar | Spotlight on antibody–drug conjugates in cancer